var data={"title":"Difluprednate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Difluprednate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/367270?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=difluprednate-drug-information\" class=\"drug drug_general\">see &quot;Difluprednate: Drug information&quot;</a> and <a href=\"topic.htm?path=difluprednate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Difluprednate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741203\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Durezol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49820846\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Durezol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20882302\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Ophthalmic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20882310\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=difluprednate-drug-information\" class=\"drug drug_general\">see &quot;Difluprednate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endogenous anterior uveitis:</b> Children &ge;2 years and Adolescents: Ophthalmic: Limited data available: Instill 1 drop into conjunctival sac of the affected eye(s) 4 times daily for 14 days, then taper as clinically indicated (Sheppard, 2014; Slabaugh, 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Inflammation associated with ocular surgery:</b> Infants, Children, and Adolescents: Ophthalmic: Instill 1 drop in conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery, continue for 2 weeks, then decrease to 2 times daily for 1 week, then taper based on response </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endogenous anterior uveitis:</b> Ophthalmic: Instill 1 drop into conjunctival sac of the affected eye(s) 4 times daily for 14 days, then taper as clinically indicated</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Inflammation associated with ocular surgery:</b> Ophthalmic: Instill 1 drop in conjunctival sac of the affected eye(s) 4 times daily beginning 24 hours after surgery, continue for 2 weeks, then decrease to 2 times daily for 1 week, then taper based on response</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in manufacture''s labeling; however, dosage adjustment unlikely due to low systemic absorption.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741238\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Ophthalmic: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Durezol: 0.05% (5 mL) [contains edetate sodium (tetrasodium), polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741204\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20882311\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Wash hands prior to use. Avoid contact of bottle tip with skin or eye; ocular solutions can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may occur from using contaminated solutions. Remove contact lenses prior to administration and wait at least 10 minutes before reinserting soft contact lenses. The use of the same bottle for both eyes is not recommended in surgical patients. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741228\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 15&deg;C to 25&deg;C (59&deg;F to 77&deg;F); do not freeze. Protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20882303\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of inflammation and pain following ocular surgery (FDA approved in pediatric patients [age not specified] and adults); treatment of endogenous anterior uveitis (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9606264\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Durezol may be confused with Durasal</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741217\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Anterior chamber inflammation, blepharitis, blurred vision, cataract (secondary), conjunctival edema, corneal edema, decreased visual acuity, dry eye syndrome, eye irritation, eye pain, increased intraocular pressure, iridocyclitis, iritis, ocular hyperemia (ciliary, conjunctival, limbal), ophthalmic inflammation (postoperative), photophobia, punctate keratitis, uveitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Corneal changes (pigmentation and striae), crusting of eyelid, episcleritis, eye pruritus, foreign body sensation of eye, increased lacrimation, injected sclera, macular edema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741211\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Active viral (including herpes simplex keratitis, vaccinia, varicella) infections of the cornea or conjunctiva, fungal infection of ocular structures, or mycobacterial ocular infections</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to difluprednate, any component of the formulation, or to other corticosteroids; acute untreated ocular bacterial infection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741212\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation. Use following cataract surgery may delay healing or increase the incidence of bleb formation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Corneal perforation: Perforation may occur with topical steroids in diseases which cause thinning of the cornea or sclera.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Exacerbation of infections: May exacerbate severity of infections. Use extreme caution in patients with history of ocular herpes simplex. Re-evaluate after 2 days if symptoms have not improved. Use is contraindicated in most viral diseases of the cornea and conjunctiva and with fungal or mycobacterial ocular infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in presence of glaucoma. Prolonged use of corticosteroids may result in elevated intraocular pressure (IOP); damage to the optic nerve; and defects in visual acuity and fields of vision. Monitor IOP in any patient receiving treatment for &ge;10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunosuppression: May mask infection or enhance existing infection. The possibility of corneal fungal infection should be considered with persistent corneal ulceration during prolonged therapy; obtain cultures when appropriate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lens wearers: Contains sorbic acid which may be absorbed by contact lenses; remove contacts prior to administration and wait 10 minutes before reinserting.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For ophthalmic use only; not for intraocular administration. Initial prescription and renewal of medication for &gt;28 days should be made by health care provider only after examination with the aid of magnification such as slit lamp biomicroscopy or fluorescein staining (if appropriate). To avoid contamination, do not touch tip of container to any surface.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26337879\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Pediatric patients may be at increased risk for elevations in intraocular pressure (IOP) when using diflurprednate for uveitis (Birnbaum, 2011; Slabaugh, 2012). In one retrospective review (n=27, age range: 6 to 63 years), four of the five children (80%) treated with diflurprednate had an increase in IOP of &ge;5 mm Hg (two had increase &ge;20 mm Hg ) compared to seven out of 22 adults (32%) (three had increase &ge;20 mm Hg). Elevation of IOP responded to discontinuation of difluprednate or the addition of glaucoma medications (Birnbaum, 2011). Another retrospective review of pediatric uveitis patients (n=14, age range: 7 to 18 years) described a higher incidence of cataracts in addition to increased IOP in this patient population (Slabaugh, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299195\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741223\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=98093&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741209\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13375041\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. The amount of difluprednate absorbed systemically following ophthalmic administration is below the limit of quantification (&lt;50 ng/mL).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20882312\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Intraocular pressure in any patient receiving treatment for &ge;10 days; periodic examination of lens with prolonged use (&gt;28 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741229\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Corticosteroids inhibit the inflammatory response including edema, capillary dilation, leukocyte migration, and scar formation. Difluprednate penetrates cells readily to induce the production of lipocortins. These proteins modulate the activity of prostaglandins and leukotrienes.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6741231\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Systemic: Exposure to active metabolite is negligible with ocular administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Undergoes deacetylation to an active metabolite (DFB) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20958137\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Durezol Ophthalmic)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (5 mL): $207.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6875352\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Diflupred (BD);</li>\n      <li>Dipred (BD);</li>\n      <li>Epitopic (AE, FR);</li>\n      <li>Neopred (BD);</li>\n      <li>Predasin (BD);</li>\n      <li>Ribeca (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Birnbaum AD, Jiang Y, Tessler HH, Goldstein DA. Elevation of intraocular pressure in patients with uveitis treated with topical difluprednate. <i>Arch Ophthalmol</i>. 2011;129(5):667-668.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/difluprednate-pediatric-drug-information/abstract-text/21555625 /pubmed\" target=\"_blank\" id=\"21555625 \">21555625 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Durezol ophthalmic emulsion (difluprednate) [prescribing information]. Fort Worth, TX: Alcon Laboratories; May 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Korenfeld MS, Silverstein SM, Cooke DL, et al. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. <i>J Cataract Refract Surg</i>. 2009; 35(1):26-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/difluprednate-pediatric-drug-information/abstract-text/19101421/pubmed\" target=\"_blank\" id=\"19101421\">19101421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. <i>Invest Ophthalmol Vis Sci</i>. 2014;55(5):2993-3002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/difluprednate-pediatric-drug-information/abstract-text/24677110 /pubmed\" target=\"_blank\" id=\"24677110 \">24677110 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slabaugh MA, Herlihy E, Ongchin S, van Gelder RN. Efficacy and potential complications of difluprednate use for pediatric uveitis. <i>Am J Ophthalmol</i>. 2012;153(5):932-938.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/difluprednate-pediatric-drug-information/abstract-text/22265149 /pubmed\" target=\"_blank\" id=\"22265149 \">22265149 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 98093 Version 29.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6741203\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F49820846\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F20882302\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F20882310\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6741238\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F6741204\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20882311\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F6741228\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F20882303\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F9606264\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6741217\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F6741211\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6741212\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26337879\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299195\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6741223\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F6741209\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13375041\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F20882312\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6741229\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F6741231\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F20958137\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6875352\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/98093|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=difluprednate-drug-information\" class=\"drug drug_general\">Difluprednate: Drug information</a></li><li><a href=\"topic.htm?path=difluprednate-patient-drug-information\" class=\"drug drug_patient\">Difluprednate: Patient drug information</a></li></ul></div></div>","javascript":null}